Long-term avelumab in advanced non-small-cell lung cancer: summaries and post hoc analyses from JAVELIN Solid Tumor

BACKGROUND: This study examined patients with advanced non-small-cell lung cancer who received long-term avelumab (anti-PD-L1) in a large phase Ib trial (JAVELIN Solid Tumor). METHODS: Patients receiving >2 years of avelumab were reviewed and exploratory descriptive analyses were conducted. RESUL...

Descripción completa

Detalles Bibliográficos
Autores principales: Hrinczenko, Borys, Iannotti, Nicholas, Goel, Sanjay, Spigel, David, Safran, Howard, Taylor, Matthew H, Bennouna, Jaafar, Wong, Deborah J, Kelly, Karen, Verschraegen, Claire, Bajars, Marcis, Manitz, Juliane, Ruisi, Mary, Gulley, James L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Medicine Ltd 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9066292/
https://www.ncbi.nlm.nih.gov/pubmed/35144482
http://dx.doi.org/10.2217/fon-2021-0930

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9066292/
https://www.ncbi.nlm.nih.gov/pubmed/35144482
http://dx.doi.org/10.2217/fon-2021-0930

Ejemplares similares